#Japan #Tokyo #gene therapy #Richmond Pharmacology #CRISPR-Cas9

Upcoming Seminar on Gene Editing & Therapy

The world of gene editing and therapy is rapidly advancing, particularly in the UK, which has become a hub for innovative research and collaboration. Richmond Pharmacology, a prominent UK-based contract research organization (CRO), is hosting a seminar focusing on the latest developments in in vivo gene editing and silencing medications. This seminar provides a unique opportunity for Japanese pharmaceutical and biotech companies to gain insights into the UK's regulatory advantages and to understand why now is the time to consider conducting clinical trials in the UK.

Background on Richmond Pharmacology

Richmond Pharmacology has played a pivotal role in supporting groundbreaking gene therapies. They made headlines by collaborating with Intellia in a landmark trial where the CRISPR-Cas9 treatment, NTLA-2001, was administered to patients suffering from ATTR amyloidosis. This marked a critical milestone in clinical development history, showcasing the potential of gene editing technologies.

Seminar Objectives

Scheduled for June 4th, 2025, this seminar will feature notable representatives from various sectors, including the UK Regulatory Authority (MHRA), the National Health Service (NHS), and the Cell & Gene Therapy Catapult. These experts will share valuable information about the current state of clinical trials in in vivo gene editing in the UK.

Participants will receive practical insights into regulatory frameworks, the flexibility of patient recruitment, and the societal acceptance of advanced medical technologies, effectively addressing the question, ‘Why the UK, now?’

Key Topics to be Covered

The seminar will delve into multiple essential topics, including:

• - Accelerating Clinical Trials: Learn from the 'Faster Answers' initiative that illustrates how swift trial implementation is achievable.
• - MHRA Insights: Understand the support mechanisms available for research in advanced medical fields from the MHRA’s perspective.
• - Regulatory Environment: Gain insights into the robust and trustworthy regulations that characterise the UK’s approach to clinical trials.
• - Diverse Patient Recruitment: Discover the advantages of the UK’s varied patient demographics and recruitment strategies.
• - Public Understanding of Gene Analysis: Addressing the social acceptance and understanding of gene therapy technologies.

Networking Opportunities

At the end of the event, participants can enjoy a networking session, allowing for exchanges of ideas and fostering collaborative opportunities among attendees and speakers. This facilitates connection-building in the fast-evolving world of gene therapy.

Event Details

• - Date: June 4, 2025
• - Time: Doors open at 13:30, seminar starts at 14:00
• - Venue: Nihonbashi Life Science Hub, Room A, Tokyo, Japan
• - Cost: Free
• - Capacity: 100 participants (Registration will close when the limit is reached)
• - Registration Link: Peatix Registration

Important Dates

• - Registration Deadline: May 30, 2025, by 18:00

Host and Collaborators

This seminar is organized by Richmond Pharmacology Limited, in collaboration with Magoneko Solutions, and with support from the British Embassy in Japan, MHRA, and Cell & Gene Therapy Catapult. Notable speakers will include experts from various organizations who will provide a broad perspective on gene therapy development.

Overall, this seminar promises to be an enlightening experience for anyone looking to understand the future of gene editing therapies and regulatory environments.

For more details, please contact: [email protected].